Key result
Compound 34 displayed IC50 values of 2.14 and 4.88 μM against the replication of H3N2 and H1N1 strains, respectively, without apparent cytotoxicity on MDCK cells.
Why the study?
Quinolin-2-one possesses a wide variety of biological activities, but the anti-influenza activities of quinolin-2-one-containing compounds were rarely reported.
3-aryl-quinolin-2-one derivatives, particularly compound 34, show promise as novel antiviral agents against influenza A virus.
3-Aryl-quinolin-2-ones merit preclinical testing; leaves open clinical translation for influenza.
Quinolin‐2‐one represents an important and valuable chemical motif that possesses a wide variety of biological activities; however, the anti‐influenza activities of quinolin‐2‐one‐containing compounds were rarely reported. Herein, we describe the screening and identification of 3‐aryl‐quinolin‐2‐one derivatives as a novel class of antiviral agents. The 3‐aryl‐quinolinone derivatives were synthesized via an efficient copper‐catalyzed reaction cascade that we previously developed. Using this synthetic method, preliminary structure–activity relationships of this scaffold against the influenza A virus infection were systematically explored. The most potent compound 34 displayed IC 50 values of 2.14 and 4.88 μM against the replication of H3N2 (A/HK/8/68) and H1N1 (A/WSN/33) strains, respectively, without apparent cytotoxicity on MDCK cells. We further demonstrated that 27 and 34 potently inhibited the plaque formation of the IAV, rendering this scaffold attractive for pursuing novel anti‐influenza agents.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2022) studied Influenza A virus infection. 3-aryl-quinolin-2-one derivatives (compound 34) was evaluated on Inhibition of viral replication (IC50) (IC50 2.14 and 4.88 μM). Compound 34 displayed IC50 values of 2.14 and 4.88 μM against the replication of H3N2 and H1N1 strains, respectively, without apparent cytotoxicity on MDCK cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: